Stroke associated with atrial fibrillation …

Stroke & Vascular Disorders

Updated 11.23.2023
Released 06.20.1996
Expires For CME 11.23.2026

Stroke associated with atrial fibrillation

Authors: Gabriela Trifan MD, Fernando Testai MD PhD

See Contributor Disclosures

Editor: Steven R Levine MD

Stroke associated with atrial fibrillation

In This Article

Quick Link

Introduction

Overview

Stroke is the leading cause of disability in the United States, with approximately 795,000 people experiencing a new or recurrent stroke each year (85). Cardioembolism is a particularly disabling stroke subtype that accounts for 20% to 30% of all stroke cases. Observational studies demonstrated that almost half of the cardioembolic strokes are related to atrial fibrillation. In this article, the authors discuss the association of atrial fibrillation with stroke, the role of anticoagulation in stroke prevention, the available risk stratification tools, and the pathogenic mechanisms of thrombus formation associated with this cardiac arrhythmia.

Key points

	• Atrial fibrillation confers a 3- to 5-fold increase in stroke risk and accounts for 15% to 30% of all ischemic strokes.
	• Prolonged cardiac monitoring is superior to short-term monitoring for the detection of occult atrial fibrillation.
	• Patients with atrial fibrillation and a CHA₂DS₂-VASc score of 0 in men and 1 in women have a low stroke risk and do not require treatment with antithrombotics.
	• Patients with atrial fibrillation and a CHA₂DS₂-VASc score of 1 in men and 2 in women have an intermediate stroke risk, and treatment with oral anticoagulants should be initiated.
	• Patients with atrial fibrillation and a CHA₂DS₂-VASc score of 2 or higher in men and 3 or higher in women are at high risk for stroke, and treatment with anticoagulants is recommended.
	• Direct thrombin or factor Xa inhibitors are non-inferior to warfarin in the prevention of stroke or systemic embolism, have lower incidence of major hemorrhagic complications, and are the preferred choice of anticoagulation in patients with atrial fibrillation.
	• The addition of aspirin to anticoagulation is only indicated in patients who have concomitant coronary artery disease.

Historical note and terminology

As early as 1628, Harvey had observed undulation in the right atrium of a dying animal heart (62); in 1874, Vulpian reported uncoordinated twitching of the atrium, "fremissement fibrillaire" after application of an electrical current (89). Nothnagel published three arterial pulse curves showing irregular heart rates in the mid-1800s and called the arrhythmia "delirium cordis" (64), which was defined by the complete irregularity of heartbeats continuously changing in "height and tension." However, the association between these atrial fibrillary contractions and the irregular pulse was not formally made until 1907 (18).

In 1940, Karl Paul Link synthesized dicumarol, a substance found in spoiled sweet clover known to cause a hemorrhagic disease in cattle; in 1947, its use was advocated for the prevention of cardiac embolism in patients with rheumatic atrial fibrillation (95). However, the risk of stroke in patients with chronic nonvalvular atrial fibrillation was generally believed to be too small to require medication. It was not until 1978 that the results of the Framingham Study clearly demonstrated an increase in stroke incidence in patients with chronic nonrheumatic atrial fibrillation (93). Vitamin K antagonists, including warfarin, have been the treatment of choice for the prevention of stroke or systemic embolism in patients with atrial fibrillation for many decades. However, randomized placebo-control studies and large patient-level network meta-analyses demonstrated more favorable efficacy and safety profiles of different non-vitamin K antagonist oral anticoagulants in the treatment of nonvalvular atrial fibrillation compared with warfarin and are now the recommend treatment of choice.

Clinical manifestations

Presentation and course

Atrial fibrillation is the most common sustained cardiac arrhythmia and the most common cause of cardioembolism. It has been estimated that atrial fibrillation accounts for a third of ischemic strokes (29). The classic sign of atrial fibrillation is an irregular pulse; however, between atrial fibrillation episodes, the pulse may be regular. Patients can have transient events of diaphoresis, lightheadedness, or palpitations. In general, cardioembolic stroke, either due to atrial fibrillation or other causes, has similar clinical findings. Patients present with severe deficits and clinical evidence of cortical or cerebellar dysfunction, eg, sudden onset of language deficits, apraxia, unilateral weakness, sensory loss, dyscoordination, ataxia, or hemianopia (02). Other stroke subtypes, however, including large-vessel thromboembolism and lacunar infarction, can present similarly. Thus, the neurologic examination has limited utility in making the diagnosis of atrial fibrillation-associated stroke. The concomitant occurrence of cerebral and systemic embolism is suggestive of cardioembolism. Brain imaging commonly shows cortical ischemia or concurrent infarction in multiple vascular territories. In the acute setting, angiographic studies typically reveal the abrupt cutoff of large vessels, such as the terminal internal carotid artery or the trunk of the middle cerebral artery, with or without evidence of atherosclerotic disease of the large cerebral arteries. Diagnosis of atrial fibrillation-related stroke is supported by the identification of abnormal cardiac rhythm on cardiac monitoring.

Prognosis and complications

Patients with atrial fibrillation have an increased risk of stroke ranging from less than 2% to more than 10% per year. The risk of stroke increases with different traditional vascular risk factors, including age, sex, hypertension, diabetes mellitus, and previous stroke or transient ischemic attack. The deficits in cardioembolism are usually more disabling than those seen in other stroke subtypes. As an example, the proportion of patients with increased disability, defined by a modified Rankin Scale score of 3 and above, at 6 months is 66% for cardioembolism, 32% for large artery occlusive disease, and 23% for lacunar infarction (56). Even in the setting of comparable rates of successful reperfusion for stroke, patients with atrial fibrillation have higher rates of mortality and significantly lower rates of functional independence at 3 months compared with patients with strokes related to other etiologies (51). Due to the increased disability, patients with atrial fibrillation are more likely to develop severe complications, including pneumonia, sepsis, infections, or systemic embolism. In age- and sex-adjusted analyses over a median follow-up time of 19 years, the risk of death in participants with atrial fibrillation was 2-fold higher, whereas in participants with atrial fibrillation and stroke, the risk of death was 4-fold higher compared with participants without atrial fibrillation (39).

Biological basis

Genomic data in atrial fibrillation come from linkage analysis, genome-wide association studies using genotyping array data, and coding variations from genome sequence data (76). Both common and rare genetic variants have been implicated in the development of atrial fibrillation. Common variants have a minor allele frequency higher than 1% and modestly increase the risk of atrial fibrillation. Most of these mutations are located within intronic and intergenic regions where they can alter the function of promoters and enhancers of the nearby genes (65; 67). Single nucleotide polymorphism (SNP) associated with atrial fibrillation were identified in the PITX2, KCNN3, PRRX1, CAV1, C9orf3, SYNPO2L, SYNE2, HCN4, and ZFHX3 genes.

In comparison, rare genetic variants have a minor allele frequency of less than 1% but are highly predictive of atrial fibrillation. These mutations are associated with gain or loss of function of genes encoding for cardiac gap junctions, signaling molecules, or sodium or potassium channels. An identified rare variant associated with loss of function of the TTN gene has been associated with earlier onset atrial fibrillation in patients younger than 30 years and leads to an earlier diagnosis (average of 5 years) than those without this mutation (14).

These genetic markers can identify individuals who have an increased risk of incidental atrial fibrillation and stroke even after adjustment for confounders (84). Data obtained in observational studies indicate that this genetic information can improve the accuracy of stroke risk stratification tools commonly used in clinical practice, such as the CHADS₂ and CHA₂DS₂-VASc scores (discussed below). However, gene sequencing data are not usually available for decision making, and its predictive value has not been well validated in mixed cohorts.

Etiology and pathogenesis

5.1 Pathogenesis of thromboembolism in atrial fibrillation. Most infarctions in patients with atrial fibrillation are believed to be caused by emboli originating in the left atrium, particularly the left atrial appendage. However, atrial fibrillation usually coexists with different traditional vascular risk factors, such as advanced age, arterial hypertension, diabetes, and hypercholesterolemia. This “systemic substrate” can contribute to the development of both atrial fibrillation and thromboembolism. In addition, atrial fibrillation can be seen in association with decreased left ventricular function, atherosclerosis of the aortic arch, and occlusive disease of the extra- and intracranial arteries, which are additional sources of embolism.

The detrimental effect of the systemic substrate is complemented by an “atrial substrate” or “atrial cardiomyopathy,” which is represented by the elements of the Virchow triad of thrombogenesis: blood stasis, endothelial injury, and procoagulability. Blood stasis can be explained by the hemodynamic changes that occur in the fibrillating atrium. Endothelial injury in atrial fibrillation is represented by endocardial denudation and fibroelastic infiltration. In addition, observational studies have shown that enhanced inflammation, hemostatic dysfunction, and abnormal fibrinolysis, all characteristic of procoagulable states, are common in atrial fibrillation (91).

The systemic substrate contributes to the development of atrial fibrillation, which, once formed, worsens atrial contractility and furthers the progression of the atrial cardiomyopathy by inducing structural remodeling. Thus, it is considered that the systemic substrate and the atrial substrate commonly coexist in patients with atrial fibrillation and interact with each other, both directly and indirectly, leading to the formation of microemboli and stroke (61).

5.2 Atrial fibrillation and cryptogenic stroke. Cryptogenic stroke refers to an embolic stroke of unknown origin. Large observational studies have shown that at least 40% of the cryptogenic strokes are caused by atrial fibrillation (11). The formulation of this category, though practical from a taxonomic and investigational standpoint, is hindered by its variable and rather broad definition. As an example, in the TOAST classification, cryptogenic stroke is characterized under three different scenarios: strokes with incomplete evaluation, lack of cause despite an extensive assessment, or stroke with multiple plausible causes (02).

Embolic stroke of undetermined source, a concept first introduced in 2014, is a subset of cryptogenic stroke and refers to a nonlacunar ischemic stroke that takes place in the absence of other well-defined stroke mechanisms, such as atrial fibrillation, atherosclerosis causing 50% or greater luminal stenosis in arteries supplying the area of ischemia, intracardiac thrombus, arterial dissection, or angiitis (42). From a pragmatic standpoint, the minimal workup necessary for the diagnosis of embolic stroke of undetermined source includes transthoracic echocardiogram, 24 hours of continuous heart rhythm monitoring, and vascular imaging of both the extracranial and intracranial cerebral arteries. Both cryptogenic stroke and embolic stroke of undetermined source have radiological evidence suggestive of an embolic mechanism. However, embolic stroke of undetermined source constitutes a subgroup of patients with cryptogenic stroke that have had sufficient workup to exclude common stroke etiologies.

Cryptogenic stroke is responsible for 30% of strokes, whereas embolic stroke of undetermined source is responsible for 15% of them. Paroxysmal atrial fibrillation is typically suspected in cryptogenic stroke or embolic stroke of undetermined source; however, observational studies demonstrate that these stroke subtypes have distinct characteristics. Patients with embolic stroke of undetermined source are usually younger, have milder stroke severity, and have smaller emboli than patients with atrial fibrillation (41). Also, in the Oxford Vascular Study embolic stroke of undetermined source and cryptogenic stroke patients had decreased prevalence of myocardial infarction, peripheral vascular disease, and asymptomatic extracranial carotid disease than patients with cardioembolism. The rate of recurrent stroke at 1 year was 2.8% for cryptogenic stroke and 35% for cardioembolic stroke. Also, the mortality at 1 year and 5 years was 6% and 25% for cryptogenic stroke and 41% and 65% for cardioembolic stroke, respectively (56).

The rate of detection of atrial fibrillation in patients with cryptogenic stroke increases with the length of cardiac monitoring. In the EMBRACE study, the incidence of 30-day atrial fibrillation of at least 30 seconds detected by continuous cardiac event monitoring in patients with cryptogenic stroke was 16.1% (35). In comparison, in the CRYSTAL-AF study, which utilized an implantable cardiac monitoring, the rate of atrial fibrillation in patients with cryptogenic stroke was 8.6% at 6 months, 12.4% at 12 months, and 30% at 36 months (78). Similarly, in the ASSERT study, patients with a recently implanted pacemaker or defibrillator with at least one risk factor for stroke and no history of atrial fibrillation were followed for approximately 2.5 years. Among the individuals with stroke, 27% of the patients had no evidence of atrial fibrillation in the 30 days preceding the stroke, and 16% had atrial fibrillation detected only after the stroke (12). Together, these results indicate that the dysrhythmia that defines atrial fibrillation, although undoubtedly associated with cerebral ischemia, is not a necessary step in the pathogenesis of cryptogenic stroke or embolic stroke of undetermined source. These observations have led to the development of the concept of “atrial cardiomyopathy” or “atrial cardiopathy,” which refers to the anatomic and physiologic changes associated with atrial dysfunction that precede atrial fibrillation but may actively contribute to left atrial thromboembolism.

Atrial cardiomyopathy is defined by the presence of at least one of the following factors: (1) left atrial structural abnormalities evidenced by echocardiography or cardiac MR, such as endothelial dysfunction, fibrosis, impaired myocyte function, or chamber dilatation; (2) electrocardiographic evidence of left atrial dysfunction, including increased P-wave terminal force velocity in lead V1 (PTFV1) greater than 5000 μV·ms; or (3) increased levels of biochemical markers of cardiac dysfunction, including increased troponins or serum N-terminal pro-brain natriuretic peptide (NT-proBNP) levels greater than 250 pg/mL (48). Multiple mechanisms have been associated with the development of atrial cardiomyopathy, including: (1) hereditary muscular dystrophies cause myocyte degeneration and fatty or fibrotic changes in the atrial fibers; (2) congestive heart failure leads to atrial fibrosis and remodeling, along with calcium channel abnormalities; (3) obstructive sleep apnea is associated with slowing of cardiac conduction; (4) in the elderly there are degenerative atrial fibrotic changes; and (5) hypertension and obesity cause left atrium enlargement and P-wave abnormalities whereas diabetes and valvular diseases cause fibrotic changes and structural remodeling (37).

It has been observed that atrial cardiopathy is associated with cerebral embolism in 10% of cases, even in the absence of atrial fibrillation (96). Also, secondary analysis of the WARSS trials shows that patients with serologic evidence of atrial cardiopathy have a lower risk of recurrent stroke or death when treated with anticoagulation rather than aspirin (60).

Another entity thought to be a precursor of atrial fibrillation and embolic stroke is atrial-heart rate event. Atrial-heart rate events are brief asymptomatic episodes of atrial tachyarrhythmia and can include brief episodes of atrial fibrillation or atrial flutter, detected only during prolonged use of cardiac implanted electronic devices. Atrial-heart rate events are considered to be a separate entity from atrial fibrillation, although presence of atrial-heart rate event longer than 5 minutes has a 6-fold increased risk of developing atrial fibrillation and a 2- to 2.5-fold increase in the risk of stroke. The overall absolute stroke risk is lower though compared with patients diagnosed with atrial fibrillation (28). There is uncertainty on best management for atrial-heart rate events.

Epidemiology

Atrial fibrillation is the most common sustained cardiac arrhythmia. It has been estimated that atrial fibrillation affects at least 3 to 6 million people in the United States alone. Over a period of 50 years of observation from the Framingham Heart Study, the age-adjusted prevalence and incidence of atrial fibrillation approximately quadrupled for both males (prevalence from 2% to 10%, incidence from 4 to 13 per 1000 person-years) and females (prevalence from 1% to 5%, incidence from 3 to 9 per 1000 person-years) (79). Due to the increase in life expectancy, the prevalence of atrial fibrillation is estimated to rise to 12.1 million by 2030. The total incidence of atrial fibrillation in the United States adult population was estimated at 1.2 million cases in 2010, and this is expected to increase to 2.6 million by 2030 (85). The prevalence of atrial fibrillation is higher among Caucasians. After adjustment for risk factors, Blacks (OR: 0.49; 95% CI: 0.47 to 0.52), Asian people (OR: 0.68; 95% CI: 0.64 to 0.72), and Hispanic people (OR: 0.58; 95% CI: 0.55 to 0.61) have significantly lower rates of atrial fibrillation than Caucasians (85).

Owing to the association of atrial fibrillation with age, the prevalence, incidence, and proportion of strokes associated with atrial fibrillation increase sharply with age.

Social determinants of atrial fibrillation and health equity have been investigated. Individuals living in intermediate poverty neighborhoods had an elevated adjusted odds of 5-year incident atrial fibrillation (OR: 1.23; 95% CI: 1.01 to 1.48), compared to individuals residing in lower-poverty neighborhoods (26). Additionally, low income in patients with prevalent atrial fibrillation (< $40,000/y) was associated with increased risk of heart failure and myocardial infarction (54). Data from an Atherosclerosis Risk in Communities study revealed that atrial fibrillation incidence decreases with progressively increasing categories of income and education (63).

Nonvalvular atrial fibrillation is associated with a 4- to 5-fold increase in the risk of stroke across all age groups (92). The risk of stroke is even higher in valvular-associated atrial fibrillation. As an example, patients with rheumatic heart disease-associated atrial fibrillation have a 17-fold increase in the risk of stroke (93). Similarly, mitral stenosis increases the risk of stroke 20 times over nonatrial fibrillation patients.

Differential diagnosis

Although most strokes in patients with atrial fibrillation are believed to originate in the left atrium, other potential causes of embolic stroke, such as carotid artery stenosis or aortic arch plaque may coexist in these patients. About 60% to 80% of individuals with established atrial fibrillation also have hypertension, which predisposes them to small vessel occlusive disease, another common stroke mechanism (88). Of major clinical importance is the association of atrial fibrillation and aortic arch atheroma. The Stroke Prevention in Atrial Fibrillation investigators reported a series of 382 patients with high-risk nonvalvular atrial fibrillation, of whom 35% had complex aortic plaques. Patients with complex plaques and atrial fibrillation had a significantly higher stroke risk per year (12% to 20%) compared to patients with atrial fibrillation alone (1.2%), suggesting that aortic arch atheroma is an important additional source of emboli (03). Complex plaques are characterized by surface abnormalities (ulcerations, mobile components) and increased plaque thickness of at least 4 mm. Descending aorta seems to be preferentially involved in cerebral embolism whereas complex plaques found in the ascending and transverse portions of the aorta appear to be involved in both cerebral and peripheral embolic events. Complex aortic plaques are also associated with a higher prevalence of left atrial abnormalities or endocardial abnormalities in patients with atrial fibrillation, suggesting a possible synergistic effect (10).

The presence of carotid atherosclerosis or plaque is another important competing mechanism for stroke in patients with atrial fibrillation. The prevalence of carotid atherosclerosis or plaque in patients with atrial fibrillation increases with age, from 38% in patients under 57-years-old (07) to 65% in patients older than 75 (06); patients who are started on anticoagulation for atrial fibrillation and have carotid atherosclerosis changes of carotid plaque of at least 50% have a 40% nonsignificant increase in risk of stroke or transient ischemic attack compared with patients without carotid plaque (06). For patients not on anticoagulation, presence of carotid changes is associated with 56% significant increased risk of stroke, even after adjustment for CHA₂DS₂-VASc score (07).

Diagnostic workup

The aim of the diagnostic workup in patients presenting with ischemic stroke and atrial fibrillation is to exclude coexistent causes of stroke that may affect management. Carotid Doppler in addition to transcranial Doppler or other non-invasive angiographic studies, such as magnetic resonance angiography or computed tomography angiography, should be performed to rule out large artery occlusive disease. Echocardiography is recommended to assess whether cardiac disease is present or absent, in particular, valvular heart disease (eg, mitral stenosis), decreased left ventricular ejection function, left ventricular hypertrophy, or left atrial dilatation. In addition, echocardiography serves in the search for other potential sources of cardiac embolism, such as cardiac tumor, interatrial septal aneurysm, and patent foramen ovale.

Transesophageal echocardiography is clearly superior to transthoracic echocardiography for the detection of left atrial thrombi (particularly in the appendage) and is considered the gold standard in assessing aortic arch atherosclerosis. In addition, transesophageal echocardiography allows depiction of spontaneous echo contrast in the atrium and reduced left atrial appendage peak flow velocities, both being important features independently associated with increased thromboembolic risk in patients with atrial fibrillation (97). Despite the diagnostic advantages of transesophageal echocardiography, the use of this relatively invasive, albeit safe, procedure may have little impact on treatment decisions except for selected cases because anticoagulation is the treatment of choice in stroke patients with atrial fibrillation.

The standard of care for identifying atrial fibrillation after an ischemic stroke involves use of prolonged cardiac monitoring. The yield of cardiac monitoring in detection of atrial fibrillation increases with the recording duration. In the STROKE-AF trial of patients with an implantable cardiac monitor inserted within 10 days of an index stroke, atrial fibrillation detection at 12 months lasting more than 30 seconds was significantly higher in the implantable cardiac monitor group versus the control group (12.1% vs. 1.8%; hazard ratio: 7.4 [95% CI: 2.6 to 21.3]; P < 0.001) (09). The risk of stroke seems to increase in proportion to the atrial fibrillation burden. The rate of thromboembolic events is 1.49% per year in patients with paroxysmal atrial fibrillation, 1.95% in those with permanent atrial fibrillation, and 1.83% in persistent atrial fibrillation (57). The KP-RHYTHM study analyzed a cohort of 1965 adults with paroxysmal atrial fibrillation not on anticoagulation. Higher atrial fibrillation burden (defined as greater than 11.4% of time spent in atrial fibrillation or atrial flutter during 14 days of continuous cardiac monitoring) was associated with a 3-fold increase in the risk of thromboembolic events after adjusting for known stroke risk factors (36). The published results of the MONITOR AF trial, which investigated the utility of dynamic monitoring of atrial fibrillation using implantable cardiac monitoring for a mean follow-up of 24 months, showed that implantable cardiac monitoring significantly improved care pathways (tools used to guide management of complex health care decisions leading to early intervention) leading to faster onset of treatment (median time to antiarrhythmic drug therapy start was 36 days in the implantable monitor group vs. 46 days in the non-implantable cardiac monitoring group), improved rhythm control (time to first ablation, 5 vs. 14 months, respectively), and significant reduced atrial fibrillation–related morbidity and mortality (52).

A newly described entity, atrial fibrillation discovered after stroke, refers to atrial fibrillation episodes that are brief and infrequent and that can be detected with greater frequency using insertable cardiac monitors. The 3-year results from the STROKE AF trial compared the rates of atrial fibrillation detection between an insertable cardiac monitors versus site-specific usual care in patients with prior ischemic stroke attributed to either large artery atherosclerosis or small vessel disease (08). In these patients, the incidence rate of atrial fibrillation at 3 years was 21.7% in the insertable cardiac monitor group versus 2.4% in the control group (HR: 10.0; 95% CI: 4.0 to 25.2; P < 0.001). However, uncertainty remains on the clinical significance of atrial fibrillation discovered after stroke and the appropriate management.

Management

14.1 Risk stratification. Guidelines for the prevention of stroke in patients with nonvalvular atrial fibrillation recommend the use of risk stratification tools to guide management. The scores most commonly used in clinical practice are the CHADS₂ and the CHA₂DS₂-VASc scores. The CHADS₂ score (Table 1a) incorporates five conditions: (1) recent congestive heart failure, (2) hypertension, (3) age of 75 years or older, (4) diabetes, and (5) prior stroke or transient ischemic attack. Each condition is given 1 point except for the composite of stroke or transient ischemic attach, which receives 2 points.

Table 1a. CHADS2 Score Quantification of Stroke Risk for Patients with Non-Valvular Atrial Fibrillation

CHADS₂score	Number of patients (n=1733)	Number of stroke (n=94)	NRAF crude stroke rate per 100 patient-years	NRAF adjusted stroke rate (95% CI)
0	120	2	1.2	1.9 (1.2 to 3.0)
1	463	17	2.8	2.8 (2.0 to 3.8)
2	523	23	3.6	4.0 (3.1 to 5.1)
3	337	25	6.4	5.9 (4.6 to 7.3)
4	220	19	8.0	8.5 (6.3 to 11.1)
5	65	6	7.7	12.5 (8.2 to 17.5)
6	5	2	44.0	18.2 (10.5 to 27.4)
NRAF indicates National Registry of Atrial Fibrillation. From (31).

One of the drawbacks of the CHADS₂ score is that almost 30% of the general population falls in the undetermined category, raising the question of whether these patients should be treated with anticoagulants or not. The CHA₂DS₂-VASc score (Table 1b, 1c), which is an extension of the CHADS₂ score, incorporates presence of vascular disease, age 65 to 74, and female sex as prognostic factors for stroke.

Table 1b. CHA2DS2-VASc Score

Risk Factor	Points
C	Congestive heart failure or LV ejection fraction 40% or less
H	Hypertension
A₂	Age 75 years or older
D	Diabetes mellitus
S₂	Prior Stroke, transient ischemic attack, or thromboembolism
V	Vascular disease (prior MI, peripheral artery disease, or aortic plaque)
A	Age 65 to 74 years
Sc	Sex category (female)
From (59).

The 2018 American College of Chest Physicians guidelines and 2019 American College of Cardiology/American Heart Association clinical practice guidelines recommend:

	• Men with a CHA₂DS₂-VASc score of 0 and women with a score of 1 are considered low stroke risk; anticoagulation therapy may be omitted in this group.
	• For patients with a CHA₂DS₂-VASc score of 1 (except when the patient scores 1 point due to sex only), oral anticoagulation should be initiated.
	• For men with CHA₂DS₂-VASc score of 2 or higher and women with a CHA₂DS₂-VASc score of 3 or higher, oral anticoagulation is recommended in favor of single or combined antiplatelet therapy (58; 47).

Although the CHA₂DS₂-VASc score is widely used in clinical practice, a systematic review of 19 validating studies found high heterogenicity for the assessment of stroke risks, especially for low to intermediate risk groups (87). This could be attributed, at least in part, to the inclusion of different populations. Also, all the risk stratification scales have well known shortcomings. For example:

	• Several risk factors in the CHA₂DS₂-VASc score are given the same weight; however, their contribution to stroke may be different. History of hypertension, for example, is associated with a higher risk of ischemic stroke than diabetes (75).
	• Female sex, in the absence of other vascular risk factors, does not seem to pose an increased risk of stroke. Thus, the risk of stroke for a patient with a score of 1 due to female sex is different than the risk of a patient with score of 1 due to hypertension.
	• Age is a continuous variable and establishing strict cutoffs may not accurately determine stroke risk.
	• The CHA₂DS₂-VASc score does not consider the vascular risk factor severity or how well controlled this is.
	• Risk stratification tools do not differentiate between the type and burden of atrial fibrillation (paroxysmal versus persistent or permanent).

Despite these limitations, the CHA₂DS₂-VASc score remains a fast and easy to use clinical risk stratification tool that reliably identifies patients at high risk who will benefit from initiating anticoagulation, as is currently the recommended risk stratification tool by the European and American Societies.

Table 1c. CHA2DS2-VASc Score Quantification of Stroke/TE Risk for Patients with Non-Valvular Atrial Fibrillation

CHA2DS2-VASc score	Number of patients (n=1084)	Number of stroke/TE (n=25)	TE rate during 1y (95% CI)	Adjusted TE rate for aspirin prescription
0	103	0	0% (0-0)	0%
1	162	1	0.6% (0.0-3.4)	0.7%
2	184	3	1.6% (0.3-4.7)	1.9%
3	203	8	3.9% (1.7-7.6)	4.7%
4	208	4	1.9% (0.5-4.9)	2.3%
5	95	3	3.2% (0.7-9.0)	3.9%
6	57	2	3.6% (0.4-12.3)	4.5%
7	25	2	8.0% (1.0-26.0)	10.1%
8	9	1	11.1% (0.3-48.3)	14.2%
9	1	1	100% (2.5-100)	100%
TE= thromboembolic events, including ischemic stroke, peripheral embolism, or pulmonary embolism. From (59).

14.2 Vitamin K antagonists. Previous trials have shown the benefits of vitamin K antagonists compared to placebo or to aspirin for primary and secondary stroke prevention. Stroke Prevention in Atrial Fibrillation Studies (SPAF I and II) investigated the effect of aspirin or placebo versus warfarin in patients with atrial fibrillation. In the first study, direct comparison of warfarin with aspirin was limited by the small number of thromboembolic events. In SPAF II trial, the combined use of fixed-dose warfarin (mean daily dose = 2.1 mg) with aspirin (325 mg per day) was evaluated as an alternative therapy to adjusted-dose warfarin with a target INR of 2.0 to 3.0 in patients with at least one risk factor for stroke (04). This trial was stopped early due to an elevated rate of embolism in patients treated with the combination therapy (7.9% per year) as compared to those on adjusted-dose warfarin (1.9% per year). A meta-analysis of randomized trials comparing vitamin K antagonist monotherapy and vitamin K antagonist plus aspirin with the same target INR showed an increased risk of bleeding in the combined therapy arm (OR=1.43, 95% CI: 1.00 to 2.02) (19). However, when vitamin K antagonists are used, the INR must be closely monitored as subtherapeutic INR confers a greater risk of embolic events, whereas supratherapeutic INR confers a risk of major bleeding. When INR was not maintained within the therapeutic window for more than 60% of the time, there was no net benefit from anticoagulation therapy in the prevention of vascular events (01).

Based on these studies, vitamin K antagonists became the standard of care for the prevention of stroke or systemic embolism in patients with atrial fibrillation until the introduction of the direct oral anticoagulants, which are now considered the standard of care for the treatment of nonvalvular atrial fibrillation. Warfarin, however, remains the agent of choice in valvular heart disease conditions.

14.3 Nonvitamin K antagonists or direct oral anticoagulants. Direct oral anticoagulants are non-vitamin K antagonists that have been approved by the United States Food and Drug Administration as alternatives to warfarin in the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. The anticoagulant effect of these agents is exerted by either direct inhibition of thrombin (dabigatran) or factor Xa (apixaban, rivaroxaban and edoxaban). In general, these agents are considered noninferior to warfarin with the advantage of having a lower rate of intracerebral hemorrhage. In addition, they are administered as a fixed dose, do not require laboratory monitoring, and have very limited drug interactions (20). The rates of embolism and cerebral hemorrhage observed with each of these agents are shown in Table 2.

Table 2. Direct Oral Anticoagulants

	RE-LY	ROCKET-AF	ARISTOTEL	ENGAGE AF-TIMI
Drug Dose	Dabigatran 110 mg low-dose 150 mg high-dose	Rivaroxaban 15 mg low-dose 20 mg high-dose	Apixaban 2.5 mg low-dose 5 mg high-dose	Edoxaban 30 mg low-dose 60 mg high-dose
Mechanism of action	Direct factor IIa inhibitor	Direct factor Xa inhibitor	Direct factor Xa inhibitor	Direct factor Xa inhibitor
Time to maximum inhibition	0.5 to 2 hours	1 to 4 hours	1 to 4 hours	1 to 2 hours
Half life	12 to 17 hours	5 to 13 hours	8 to 15 hours	6 to 11 hours
Renal excretion	85%	66%	27%	50%
Metabolic drug interactions	P-gp inhibitors: reduce dose or avoid* P-gp inducers: avoid	CYP3A4 and P-gp: avoid CYP3A4 and P-gp inducers: caution with use	CYP3A4 and P-gp: avoid CYP3A4 and P-gp inducers: caution with use	P-gp inhibitors: reduce dose P-gp inducers: avoid
Efficacy
Stroke or systemic embolism (% per year)	1.7% warfarin 1.5% low dose 1.1% high dose	2.4% warfarin 2.3% rivaroxaban	1.6% warfarin 1.3% apixaban	1.5% warfarin 1.6% low-dose 1.2% high-dose
Safety
Major bleeding (% per year)	3.6% warfarin 2.9% low-dose 3.3% high-dose	3.4% warfarin 3.6% rivaroxaban	3.1% warfarin 2.1% apixaban	3.4% warfarin 1.6% low-dose 2.8% high-dose
Intracranial hemorrhage (% per year)	0.7% warfarin 0.2% low-dose 0.3% high-dose	0.7% warfarin 0.5% rivaroxaban	0.8% warfarin 0.3% apixaban	0.5% warfarin 0.2% low-dose 0.3% high-dose
Myocardial infarction (% per year)	0.6% warfarin 0.8% low-dose 0.8% high-dose	1.1% warfarin 0.9% rivaroxaban	0.6% warfarin 0.5% apixaban	0.8% warfarin 0.9% low-dose 0.7% high-dose
* P-gp=P-glycoprotein (reduce dose with concomitant verapamil dose; avoid with dronedarone) From (16; 69; 38; 34).

The AVERROES trial compared apixaban to aspirin (81- to 324 mg/day) in atrial fibrillation patients who had failed vitamin K antagonist treatment or were deemed unsuitable to be treated with warfarin. This study was terminated early as apixaban proved its superiority to aspirin for the reduction of stroke or systemic thromboembolism (HR 0.45; 95% CI: 0.32 to 0.62; P< 0.001). The rate of hemorrhagic complications was similar between both groups (0.4% per year) (15).

It should be emphasized that the studies that investigated the efficacy of direct oral anticoagulants in atrial fibrillation excluded patients with mechanical heart valves or hemodynamically significant mitral stenosis. Based on subgroup analysis of randomized trials it was suggested that direct oral anticoagulants can potentially be used in atrial fibrillation patients with mild aortic stenosis, aortic regurgitation, and mitral regurgitation (66). However, the RE-ALIGN study showed that dabigatran was associated with an excess risk of thromboembolic events and hemorrhagic complications compared with warfarin in atrial fibrillation patients with mechanical heart valves (25).

The 2019 American College of Cardiology/American Heart Association Clinical Practice Guidelines and the Heart Rhythm Society Guideline for the Management of Patients with Atrial Fibrillation recommend using direct oral anticoagulants over warfarin in eligible patients with atrial fibrillation, except for the patients with moderate to severe mitral stenosis or mechanical heart valve, where warfarin remains the drug of choice (47). These guidelines are in line with the 2021 European Heart Rhythm Association Practical guide. The term “non-valvular” atrial fibrillation has been removed from clinical practice and denotes atrial fibrillation associated with all native valvular stenosis or valvular insufficiencies and bioprosthetic valves. Valvular atrial fibrillation refers to atrial fibrillation due to mechanical heart valve or moderate to severe mitral stenosis (82).

Understanding that undiagnosed atrial fibrillation may be the culprit of stroke in individuals with cryptogenic ischemia, two large, randomized studies investigated the beneficial effect of direct oral anticoagulants for the prevention of recurrent ischemic strokes in patients with embolic stroke of undetermined source. NAVIGATE-ESUS (rivaroxaban for stroke prevention after embolic stroke of undetermined source) evaluated the efficacy of rivaroxaban 15 mg daily versus 100 mg aspirin daily for preventing recurrent strokes or systemic embolism in patients with recent embolic stroke of undetermined source. The trial was terminated early due to an increased risk of bleeding seen with rivaroxaban (1.8% annual rate) compared to aspiring (0.7% annual rate). The trial also failed to demonstrate the benefit of using rivaroxaban for preventing recurrent ischemic strokes (4.7% annual rate of recurrent strokes for both rivaroxaban and aspirin groups) (43). The RE-SPECT ESUS trial compared the efficacy and safety of dabigatran 150 mg twice daily versus aspirin 100 mg daily in the prevention of recurrent ischemic strokes after embolic stroke of undetermined source. The annual rate of recurrent stroke was similar in patients treated with dabigatran (4.1%) and aspirin (4.8%). The rates of major bleeding were similar between both groups (1.7% annual rate for dabigatran vs. 1.4% annual rate for aspirin) (21).

ARCADIA was another major trial that investigated the use of anticoagulation versus antiplatelets in embolic stroke of undetermined source with evidence of atrial cardiopathy (49). The trial’s interim results were recently presented at the 2023 European Stroke Conference. ARCADIA enrolled patients diagnosed with embolic stroke of undetermined source in the past 6 months who had evidence of atrial cardiopathy defined by one of three biomarkers (ECG marker reflective of left atrial abnormalities, an enlarged left atrium on echocardiography, or a serum NT-proBNP level above 250 pg/mL). Patients were randomized to apixaban 5 mg (or 2.5 mg, if indicated) twice daily plus placebo or aspirin 81 mg daily plus placebo. The study failed to show benefit for preventing recurrent strokes with use of apixaban compared to aspirin (4.4% rate in both groups for an HR of 1.00; 95% CI: 0.64 to 1.55), and recruitment was terminated early. The rate of all-cause mortality was slightly higher in the apixaban group (1.8% vs. 1.2%), but the difference was not significant (HR 1.53; 95% CI: 0.63 to 3.74).

Based on these trials, the use of anticoagulation in unselected cases of embolic stroke of undetermined source is not currently recommended.

14.4 Antiplatelet agents. Multiple studies have shown the superiority of anticoagulation compared to antiplatelets alone for the management of atrial fibrillation–related complication; therefore, use of antiplatelets alone is not currently recommended for atrial fibrillation management (50). Combined antiplatelet-anticoagulant therapy may only be indicated for patients with atrial fibrillation who also have acute coronary syndromes or those who undergo percutaneous coronary intervention with or without stenting.

14.5 Initiation of anticoagulation after acute stroke. Timing to initiate anticoagulation therapy in atrial fibrillation patients with acute ischemic stroke is controversial.

In most cases, anticoagulation can be safely resumed 14 days post stroke (50). However, different factors can influence this decision, including size of stroke or presence of hemorrhagic conversion. For patients at high risk of recurrent cardiogenic embolism, including those with valvular heart disease, intracardiac thrombus, or congestive heart failure, early anticoagulation is generally advised. In patients with large infarcts, uncontrolled hypertension, or those at relatively low risk for early recurrence, delaying anticoagulation for several days to a week may reduce the risk of hemorrhagic transformation. Following significant hemorrhagic infarction, anticoagulation should generally be delayed.

With the widespread use of direct oral anticoagulants for stroke prevention in patients with atrial fibrillation, timing of resuming anticoagulation needs to balance the risk for recurrent ischemic events with the risk for hemorrhagic transformation. The 2018 American Heart Association/American Stroke Association guidelines recommend starting anticoagulation within 4 to 14 days post ischemic stroke (72; 80). In comparison, the European Heart Rhythm Association of the European Society of Cardiology recommends using the “1-3-6-12 days” rule. This means that anticoagulation can be resumed 1 day after a transient ischemic attack, 3 days after a minor ischemic stroke (defined as NIHSS less than 8), 6 days after a mild stroke (defined as NIHSS between 8-15), and 12 days after a large stroke (NIHSS more than 15) (44). A study has also shown that for patients with mild to moderate strokes, early direct oral anticoagulation initiation appears safe (27).

14.6 Rhythm- and rate-control. One of the largest trials of rate versus rhythm control in atrial fibrillation, the AFFIRM trial showed that achieving a normal sinus rhythm does not significantly reduce the risk of stroke (86). The majority of strokes occurred in patients who stopped anticoagulation, suggesting that the treatment of atrial dysrhythmia may not completely eliminate the thrombogenic substrate observed in atrial fibrillation. However, the RAFAS Trial, which investigated early rhythm control versus standard care in patients with newly documented atrial fibrillation during an acute ischemic stroke, showed that at 12 months follow-up, the rates of ischemic stroke recurrence were lower than the standard care group (HR: 0.251 [log‐rank P=0.034]), with similar rates for adverse outcomes (68). Other clinical trials have also shown the benefit of rhythm control in patients with heart failure (73).

14.7 Nonpharmacological treatments. Besides anticoagulation, other nonpharmacological strategies are available for prevention of stroke in atrial fibrillation patients, including catheter ablation therapies, pulsed field ablation, or percutaneous closure of the left atrium appendage. The PROTECT atrial fibrillation trial (WATCHMAN) randomized patients with atrial fibrillation and a CHADS2 score ≥1 to percutaneous closure of the left atrium appendage versus warfarin. Patients assigned to percutaneous closure of the left atrium appendage had to be able to tolerate warfarin for 45 days after the procedure, at which time warfarin therapy was discontinued. The surgical procedure was noninferior to warfarin and had a 3 per 100 patient-year efficacy rate compared with 4.9 per 100 patient-year efficacy in the warfarin group (45). In the extended period of 4 years, the device was associated with a significant reduction in the composite outcome of stroke, systemic embolism, and cardiovascular/unexplained death, compared with warfarin (8.4% vs. 13.9%) (74). However, this benefit was largely driven by a reduction in the rate of hemorrhagic stroke, with no effect on the occurrence of ischemic stroke. Additionally, the PREVAIL trial showed that left atrial appendage occlusion was noninferior to warfarin for ischemic stroke prevention or side effects more than 7 days post-procedure (rate ratio: 1.07; 95% CI: 0.57 to 1.89). Current guidelines recommend considering the use of left atrial appendage closure in patients at high bleeding risk from oral anticoagulation (50).

Outcomes

The selection of antithrombotic agents in atrial fibrillation depends on the predicted risk of thromboembolism and hemorrhagic complications. When anticoagulation is warranted, direct oral anticoagulants are usually preferred over warfarin given the same proven efficacy as vitamin K antagonists and a lower risk for bleeding. Several scales exist to quantify bleeding risk: (1) HEMORR2HAGES, (2) ATRIA and (3) HAS-BLED. The 2012 AMADEUS trial compared the predictive abilities of these scales for clinically relevant intracranial bleeding and HAS-BLED demonstrated superiority over the other scales (05). Both HEMORR2HAGES and HAS-BLED scores are being used in clinical practice.

The HEMORR2HAGES score is calculated by adding 1 point for each of the following factors: hepatic or renal disease, ethanol abuse, malignancy, old age (older than 75 years), reduced platelet counts or platelet dysfunction, uncontrolled hypertension, anemia, genetic factors, elevated fall risk, or stroke; 2 points were added for rebleeding (32). HAS-BLED score has fewer components and adds 1 point for each of these factors: hypertension, abnormal renal and liver function (1 or 2 points), stroke, bleeding, labile INRs, elderly, and drugs or alcohol (1 or 2 points) (70).

Table 3a. Incidence of Major Bleeding Stratified by the HEMORR2HAGES Score

HEMORR2HAGES score	Number of patients	Number of bleeding	Bleeding per 100 patient-years warfarin (95% CI)
0	209	4	1.9 (0.6-4.4)
1	508	11	2.5 (1.3-4.3)
2	454	20	5.3 (3.4-8.1)
3	240	15	8.4 (4.9-13.6)
4	106	9	10.4 (5.1-18.9)
5 or greater	87	8	12.3 (5.8-23.1)
Any score	1604	67	4.9 (3.9-6.3)
Data from the National Registry of Atrial Fibrillation (32).

Table 3b. Incidence of Major Bleeding Stratified by HAS-BLED Score

HAS-BLED score	Number of patients	Number of bleeding	Bleeding per 100 patient-years (%)
0	798	9	1.13
1	1286	13	1.02
2	744	14	1.88
3	187	7	3.74
4	46	4	8.70
5	8	1	12.50
6	2	0	0.0
7	0	-	-
8	0	-	-
9	0	-	-
Any score	3 071	48	1.56
From (70).

The annual rate of major hemorrhage is estimated at 1% for aspirin and 3% to 4% for warfarin (04). Direct oral anticoagulants have a 30% to 50% reduced risk of major bleeding, including intracranial hemorrhage, compared to warfarin. The use of dual therapy (warfarin and clopidogrel) or triple therapy (warfarin, aspirin, and clopidogrel) increases the risk of fatal and nonfatal bleeding 1.7 to 3.7 times compared to warfarin, respectively (40). Also, the addition of aspirin to direct oral anticoagulants has an additive effect on the risk of bleeding (83). In general, the combination of antithrombotics is not recommended for patients with atrial fibrillation. However, this may be indicated in patients with coronary artery disease or those undergoing cardiac stent procedures.

In case of emergency, the effect of warfarin can be reverted using intravenous vitamin K and prothrombin complex concentrate (30). In the case of dabigatran, the monoclonal antibody fragment idarucizumab reverses the anticoagulant effect in a complete and durable fashion within minutes of administration (71), whereas a single bolus of andexanet alfa can be used for reversal of apixaban and rivaroxaban (17).

Special considerations

16.1 Perioperative management of antithrombotics in atrial fibrillation. The question of holding anticoagulation perioperatively and using other protective agents (eg, low molecular weight heparin) is still a matter of debate. Existing data suggest that the risk of stroke increases significantly in the first 2 weeks after stopping the anticoagulant (13). The BRIDGE trial concluded that holding warfarin for elective procedures without any bridging was noninferior to using low molecular weight heparin for arterial thromboembolism prevention (22). The risk of bleeding was reduced in patients without bridging compared with patients who were bridged (RR 0.41; 95% CI, 0.20 to 0.78). Findings are similar when direct oral anticoagulants are used: a subgroup analysis of the RE-LY trial looked at patients who interrupted dabigatran before surgery and used bridging anticoagulation versus no bridging and found no significant differences in the rates of thromboembolism or systemic emboli among groups (23). Bridging anticoagulation is not recommended for unselected cases but is advised for patients at high risk for thromboembolism (eg, mechanical heart valve, atrial fibrillation, venous thromboembolism) (24).

16.2 Secondary atrial fibrillation. Secondary atrial fibrillation refers to the cases of atrial fibrillation that take place during the course of active medical conditions or surgical procedures. Typical scenarios include infections, pulmonary embolism, hyperthyroidism, or cardiac surgery. A substantial number of patients with secondary atrial fibrillation will spontaneously convert to sinus rhythm on correction of the underlying process. This has led to the notion that secondary atrial fibrillation is a self-limited condition that carries a more benign prognosis than primary atrial fibrillation. However, there is growing evidence that challenges this concept. New-onset atrial fibrillation during sepsis and perioperative atrial fibrillation has been associated with increased risk of stroke (90; 33). It is plausible that patients with secondary atrial fibrillation constitute a selected group of individuals with genetic or atrial factors that predispose them to develop atrial fibrillation. Guidelines do not give specific recommendations in terms of anticoagulation for patients with secondary atrial fibrillation (47). However, it is reasonable to consider active surveillance for recurrent atrial fibrillation and tailor the use of anticoagulation based on individual risk of thromboembolism.

16.3 COVID-19 and atrial fibrillation. Arrhythmias have been reported in cases of COVID-19 infection, with COVID-19-positive patients having slightly higher odds of developing atrial fibrillation compared to matched COVID-19-negative patients (OR: 1.19; 95% CI: 1.00 to 1.41; p=0.0495) (94). In a large cohort of patients across the United States, the incidence of new-onset atrial fibrillation during COVID-19 hospitalization was 5.4%, and these patients had higher rates of death (45.2% vs. 11.9%) and major cardiovascular events (23.8% vs. 6.5%) compared to patients without new-onset atrial fibrillation. However, the adjusted rates of death were similar between groups (HR: 1.10; 95% CI: 0.99 to 1.23), whereas rates for major cardiovascular events, including stroke, remained elevated in the atrial fibrillation group (HR: 1.31; 95% CI: 1.14 to 1.50) (77). The association between atrial fibrillation, COVID-19 disease, and stroke risk is complex and needs further investigation.

16.4 Management of atrial fibrillation in renal patients. Approximately 15% to 20% of the patients with chronic kidney disease have atrial fibrillation. The dose adjustments recommended for patients with chronic kidney disease are shown in Table 4. A large retrospective study looking into the use of apixaban versus aspirin in dialysis patients found that patients with atrial fibrillation on dialysis who took apixaban had a 28% lower rate of bleeding events compared to patients taking warfarin (HR: 0.72; 95% CI: 0.59 to 0.87; P< 0.001), with similar risks of stroke/systemic embolism (HR: 0.88; 95% CI: 0.69 to 1.12; P=0.29) (81). Therefore, apixaban is now considered an alternative to warfarin in patients with atrial fibrillation on dialysis.

Table 4. Dose Adjustment of Direct Oral Anticoagulants in Patients with Chronic Kidney Disease

	RE-LY	ROCKET-AF	ARISTOTEL	ENGAGE AF-TIMI
Drug	Dabigatran	Rivaroxaban	Apixaban	Edoxaban
Renal clearance	80%	35%	25%	50%
Exclusion criteria for chronic kidney disease	CrCl<30 mL/min	CrCl<30 mL/min	Serum creatinine>2.5 mg/dL or CrCl<25 mL/min	CrCl<30 mL/min
Renal function
Normal or mild impairment (CrCl 51-80 mL/min)	150 mg twice daily	20 mg once daily	5 mg once daily	60 mg (or 30 mg) once daily
Moderate impairment
(CrCl 30-50 mL/min)	150 mg twice daily	15 mg once daily	5 mg once daily*	30 mg (or 15 mg) once daily
Severe impairment
(CrCl 15-29 mL/min)	75 mg twice daily**	15 mg once daily	Not recommended	30 mg (or 15 mg) once daily
End stage chronic kidney disease (with or without dialysis)	Not recommended	Not recommended	Not recommended***	Not recommended
CrCl: creatinine clearance * Use 2.5 mg twice daily if two of the following: serum creatinine 1.5 or higher, age 80 years or older, or weight 60 kg or less. Dose determined based on modelling studies; however, this dose was not properly investigated in randomized trials. * In patients with end-stage chronic kidney disease on stable hemodialysis, prescribing information suggests the use of apixaban 5 mg twice daily with dose reduction to 2.5 mg twice daily if the patient is 80 years of age or older or weight is 60 kg or less. From (16; 38; 69; 34; 47).

Pregnancy

In general, atrial fibrillation is uncommon during pregnancy (55). In cases where anticoagulation is indicated, low molecular weight heparin should be used throughout pregnancy. Warfarin therapy in the first trimester of pregnancy is associated with fetal anomalies and is, therefore, not recommended. Similarly, limited evidence exists on the use of direct oral anticoagulants in pregnancy. Studies have shown that rivaroxaban was associated with an increased risk of miscarriages and a 4% rate of anomalies and is, therefore, not currently recommended (53).

References

01: ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12. PMID 16765759
02: Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24(1):35-41. PMID 7678184
03: Anonymous. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998;128(8):639-47. PMID 9537937
04: Anonymous. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343(8899):687-91. PMID 7907677
05: Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol 2012;60(9):861-7. PMID 22858389
06: Becattini C, Dentali F, Camporese G, et al. Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis 2018;271:177-81. PMID 29524860
07: Bekwelem W, Jensen PN, Norby FL, et al. Carotid atherosclerosis and stroke in atrial fibrillation: The Atherosclerosis Risk in Communities Study. Stroke 2016;47(6):1643-6. PMID 27217511
08: Bernstein RA, Kamel H, Granger CB, et al. Atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: 3-year results from the STROKE AF Randomized Clinical Trial. JAMA Neurology 2023:e233931.** PMID 37902733
09: Bernstein RA, Kamel H, Granger CB, et al. Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE-AF) randomized trial. JAMA 2021;325(21):2169-77 PMID 34061145
10: Blackshear JL, Pearce LA, Hart RG, et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke 1999;30(4):834-40. PMID 10187888
11: Brachmann J, Morillo CA, Sanna T, et al. Uncovering atrial fibrillation beyond short-term monitoring in cryptogenic stroke patients: three-year results from the cyptogenic stroke and underlying atrial fibrillation trial. Circ Arrhythm Electrophysiol 2016;9(1):e003333. PMID 26763225
12: Brambatti M, Connolly SJ, Gold MR, et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014;129(21):2094-9. PMID 24633881
13: Broderick JP, Bonomo JB, Kissela BM, et al. Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence. Stroke 2011;42(9):2509-14. PMID 21719769
14: Choi SH, Weng LC, Roselli C, et al. Association between titin loss-of-function variants and early-onset atrial fibrillation. JAMA 2018;320(22):2354-64. PMID 30535219
15: Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17. PMID 21309657
16: Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51. PMID 19717844
17: Connolly SJ, Crowther M, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380:1326-35. PMID 30730782
18: Cushny AR, Edmunds CW. Paroxysmal irregularity of the heart and auricular fibrillation. Am J Med Sci 1907;133:66-77.
19: Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med 2007;167:117-24. PMID 17242311
20: Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012;126(20):2381-91.** PMID 23071159
21: Diener HC, Easton JD, Granger CB, et al. Design of randomized, double-blind, evaluation in secondary stroke prevention comparing the efficacy and safety of the oral thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with embolic stroke of undetermined source (RE-SPECT ESUS). Int J Stroke 2015;10(8):1309-12. PMID 26420134
22: Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost 2015a;113:625-32. PMID 25472710
23: Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 2015b;373(9):823-33. PMID 26095867
24: Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e326S-50S.** PMID 22315266
25: Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369(13):1206-14. PMID 23991661
26: Essien UR, McCabe ME, Kershaw KN, et al. Association between neighborhood-level poverty and incident atrial fibrillation: a retrospective cohort study. J Gen Intern Med 2022;37(6):1436-43. PMID 34240286
27: Fischer U, Koga M, Strbian D, et al. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med 2023;388(26):2411-21. PMID 37222476
28: Freedman B, Boriani G, Glotzer TV, Healy JS, Kirchhof P, Potpara TS. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 2017;14(12):701-14. PMID 28682320
29: Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016;388(10046):806-17. PMID 27560276
30: Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016;24(1):6-46.** PMID 26714677
31: Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA 2001;285:2864-70. PMID 11401607
32: Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-9. PMID 16504638
33: Gialdini G, Nearing K, Bhave PD, et al. Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014;312(6):616-22. PMID 25117130
34: Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104. PMID 24251359
35: Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370(26):2467-77. PMID 24963566
36: Go AS, Reynolds K, Yang J, et al. Association of burden of atrial fibrillation with risk of ischemic stroke in adults with paroxysmal atrial fibrillation: The KP-RHYTHM Study. JAMA Cardiol 2018;3(7):601-8. PMID 29799942
37: Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterisation, and clinical implication. J Arrhythm 2016;32(4):247-78. PMID 27588148
38: Granger C, Alexander J, McMurrau J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92. PMID 21870978
39: Hald EM, Lochen ML, Mathiesen EB, et al. Atrial fibrillation, venous thromboembolism, ischemic stroke, and all‐cause mortality: the Tromsø study. Res Pract Thromb 2020;4(6):1004-12. PMID 32864551
40: Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170(16):1433-41. PMID 20837828
41: Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. Stroke 2017;48(4):867-72. PMID 28265016
42: Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13(4):429-38.** PMID 24646875
43: Hart RG, Sharma M, Mundl M, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source (NAVIGATE-ESUS). N Engl J Med 2018;378(23):2191-201. PMID 29766772
44: Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34(27):2094-106. PMID 23625209
45: Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374(9689):534-42. PMID 19683639
46: Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123(14):1501-8. PMID 21444879
47: January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019;74(1):104-32.** PMID 30703431
48: Kamel H, Okin PM, Longstreth WT Jr, Elkind MS, Soliman EZ. Atrial cardiopathy: a broadened concept of left atrial thromboembolism beyond atrial fibrillation. Future Cardiol 2015;11(3):323-31. PMID 26021638
49: Kamel H. Primary results of the atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke (ARCADIA) randomized trial. Presented at: ESOC 2023; May 24, 2023; Munich, Germany.
50: Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021;52(7):e364-467.** PMID 34024117
51: Kobeissi H, Ghozy S, Seymour T, et al. Outcomes of patients with atrial fibrillation following thrombectomy for stroke: a systematic review and meta-analysis. JAMA Network Open 2023;6(1):e2249993. PMID 36607633
52: Lakkireddy DR, Garg J, Ahmed A, et al. LB-456091-2 Dynamic data driven management of atrial fibrillation using implantable cardiac monitors – the MONITOR AF study. Heart Rhythm 2023;20(7):1085-6.
53: Lameijer H, Aalberts JJJ, van Veldhuisen DJ, Meijer K, Pieper PG. Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review. Thromb Res 2018;169:123-7. PMID 30036784
54: LaRosa AR, Claxton J, O’Neal WT, et al. Association of household income and adverse outcomes in patients with atrial fibrillation. Heart 2020;106(21):1679-85. PMID 32144188
55: Lee MS, Chen W, Zhang Z, et al. Atrial fibrillation and atrial flutter in pregnant women--a population-based study. J Am Heart Assoc 2016;5(4):e003182. PMID 27076563
56: Li L, Yiin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol 2015;14(9):903-13. PMID 26227434
57: Link MS, Giugliano RP, Ruff CT, et al. Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48). Circ Arrhythm Electrophysiol 2017;10(1):pii:e004267. PMID 28077507
58: Lip GY, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018;154(5):1121-1201. PMID 30144419
59: Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137(2):263-72. PMID 19762550
60: Longstreth WT Jr, Kronmal RA, Thompson JL, et al. Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy. Stroke 2013;44(3):714-9. PMID 23339958
61: Masawa N, Yoshida Y, Yamada T, Joshita T, Ooneda G. Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence of macroscopically visible thrombi. Virchows Arch A Pathol Anat Histopathol 1993;422(1):67-71. PMID 8438558
62: McMichael J. History of atrial fibrillation 1628–1819 Harvey-de Senac-Laënnec. Br Heart J 1982;48:193-7. PMID 7049202
63: Mou L, Norby FL, Chen LY, et al. Lifetime risk of atrial fibrillation by race and socioeconomic status: ARIC Study (Atherosclerosis Risk in Communities). Circ Arrhythm Electrophysiol 2018;11(7):e006350. PMID 30002066
64: Nothnagel H. Ueber arythmische Herzthätigkeit. Dtsch Arch Klin Med 1876;17:190-220.
65: Olesen MS, Nielsen MW, Haunsø S, Svendsen JH. Atrial fibrillation: the role of common and rare genetic variants. Eur J Hum Genet 2013;22(3):297-306. PMID 23838598
66: Owens RE, Kabra R, Oliphant CS, et al. Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review. Clin Cardiol 2017;40(6):407-12. PMID 28004413
67: Paludan-Muller C, Svendsen JH, Olesen MS. The role of common genetic variants in atrial fibrillation. J Electrocardiol 2016;49(6):864-70. PMID 27624063
68: Park J, Shim J, Lee JM, et al. Risks and benefits of early rhythm control in patients with acute strokes and atrial fibrillation: a multicenter, prospective, randomized study (the RAFAS trial). J Am Heart Assoc 2022;11(3):e023391. PMID 35043663
69: Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91. PMID 21830957
70: Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138(5):1093-100. PMID 20299623
71: Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017;377(5):431-41. PMID 28693366
72: Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018;49(3):e46-110. PMID 29367334
73: Prystowsky EN. Rate versus rhythm control for atrial fibrillation: has the debate been settled? Circulation 2022;146(21):1561-3. PMID 36409779
74: Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs. warfarin for atrial fibrillation: a randomized clinical trial. JAMA 2014;312(19):1988-98. PMID 25399274
75: Romero JR, Morris J, Pikula A. Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis 2008;2(4):287-303. PMID 19124428
76: Roselli C, Rienstra M, Ellinor PT. Genetics of atrial fibrillation in 2020:GWAS, genome sequencing, polygenic risk, and beyond. Circ Res 2020;127(1):21-33. PMID 32716721
77: Rosenblatt AG, Ayers CR, Rao A, et al. New-onset atrial fibrillation in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Registry. Circ Arrhythm Electrophysiol 2022;15(5):e010666. PMID 35475654
78: Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370(26):2478-86. PMID 24963567
79: Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015;386(9989):154-62. PMID 25960110
80: Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol 2019;18(1):117-26. PMID 30415934
81: Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138(15):1519-29. PMID 29954737
82: Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021:23(10):1612-76. PMID 33895845
83: Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015;131(5):488-94. PMID 25499873
84: Tada H, Shiffman D, Smith JG, et al. Twelve-single nucleotide polymorphism genetic risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke 2014;45(10):2856-62. PMID 25123217
85: Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation 2023;147(8):e93-621. PMID 36695182
86: Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347(23):1825-33. PMID 12466506
87: van Doorn S, Debray TPA, Kaasenbrood F, et al. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. J Thromb Haemost 2017;15(6):1065-77. PMID 28375552
88: Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation. Circ Res 2018;122(2):352-68. PMID 29348255
89: Vulpian A. Note sur les effets de la faradisation directe des ventricules du coeur chez le chien. Arch Phys Norm Pathol 1874; 6:975.
90: Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 2014;146(5):1187-95. PMID 24723004
91: Watson T, Shantsila E, Lip G. Mechanisms of thrombogenesis in atrial fi brillation: Virchow’s triad revisited. Lancet 2009;373(9658):155-66. PMID 19135613
92: Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent riskfactor for stroke: the Framingham Study. Stroke 1991;22(8):983-8. PMID 1866765
93: Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28(10):973-7. PMID 570666
94: Wollborn J, Karamnov S, Fields KG, Yeh T, Muehischlegel JD. COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. Sci Rep 2022;12(1):12014. PMID 35835807
95: Wright IS, Foley WT. Use of anticoagulants in the treatment of heart disease with special reference to coronary thrombosis, rheumatic heart disease with thromboembolic complications and subacute bacterial endocarditis. Am J Med 1947; 3:718-39. PMID 20272357
96: Yaghi S, Boehme AK, Hazan R, et al. Atrial cardiopathy and cryptogenic stroke: a cross-sectional pilot study. J Stroke Cerebrovasc Dis 2016;25(1):110-4. PMID 26476588
97: Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. J Am Coll Cardiol 1998;31(7):1622-6. PMID 9626843

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Gabriela Trifan MD

Dr. Trifan of The University of the Illinois College of Medicine has no relevant financial relationship to disclose.
See Profile
Fernando Testai MD PhD

Dr. Testai of The University of Illinois College of Medicine has no relevant financial relationship to disclose.
See Profile

Editor

Steven R Levine MD

Dr. Levine of the SUNY Health Science Center at Brooklyn has no relevant financial relationships to disclose.
See Profile

Former Authors

Neelofer Shafi MD
Gregory W Albers MD (original author), Helmi L Lutsep MD, Yvonne Schwammenthal MD, Ehud Schwammenthal MD, David Tanne MD, Salvador Cruz-Flores MD, Tagann Chaisam MD

Patient Profile

Age range of presentation: 6 to 65+ years
Sex preponderance: female>male
Heredity: Heredity may be a factor
Population groups selectively affected: Caucacians

Elderly
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Atrial fibrillation: 427.31

Cerebral embolism with cerebral infarction: 434.11
ICD-10: Atrial fibrillation and flutter: I48

Cerebral infarction due to embolism of cerebral arteries: I63.4

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Stroke associated with atrial fibrillation

Differential Diagnosis

stroke associated with carotid artery stenosis
stroke associated with aortic arch plaque
stroke associated with small-vessel ischemic disease
aortic arch atheroma
procoagulability
- carotid atherosclerosis or plaque

Also Relevant

Aortic atherosclerosis and stroke
Cerebral embolism
Ischemic stroke
Pregnancy and stroke
Stroke associated with myocardial infarction
- TIAs (carotid)
- Vertebrobasilar transient ischemic attacks

Stroke associated with atrial fibrillation

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Table 1a. CHADS2 Score Quantification of Stroke Risk for Patients with Non-Valvular Atrial Fibrillation

Table 1b. CHA2DS2-VASc Score

Table 1c. CHA2DS2-VASc Score Quantification of Stroke/TE Risk for Patients with Non-Valvular Atrial Fibrillation

Table 2. Direct Oral Anticoagulants

Outcomes

Table 3a. Incidence of Major Bleeding Stratified by the HEMORR2HAGES Score

Table 3b. Incidence of Major Bleeding Stratified by HAS-BLED Score

Special considerations

Table 4. Dose Adjustment of Direct Oral Anticoagulants in Patients with Chronic Kidney Disease

Pregnancy

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Vein of Galen malformations

Patent foramen ovale

Neuroimaging in acute stroke

Atrial myxoma

Anterior cerebral artery stroke syndromes

Hemorrhagic transformation of ischemic stroke

Intracerebral hemorrhage due to thrombolytic therapy

White matter abnormalities in the brain

This is an article preview.
Start a Free Account
to access the full version.